Aumolertinib effectively reduces clinical symptoms of an EGFR L858R-mutant non-small cell lung cancer case coupled with osimertinib-induced severe thrombocytopenia: a case report.

Hu, Yong; Quan, Ya-Ping; Duan, Yong-Wei; Li, Hao; Shen, Jie; Lin, Nan; Wang, Cheng; Tian, Bin; Li, Jia-Jia

Hu, Yong; Quan, Ya-Ping; Duan, Yong-Wei; Li, Hao; Shen, Jie; Lin, Nan; Wang, Cheng; Tian, Bin; Li, Jia-Jia.

Affiliation

Hu Y; The First Department of Oncology.
Quan YP; The First Department of Oncology.
Duan YW; The First Department of Oncology.
Li H; The First Department of Oncology.
Shen J; The First Department of Oncology.
Lin N; The First Department of Oncology.
Wang C; The First Department of Oncology.
Tian B; Pathology Department, Guiyang Public Health Clinical Center, Guizhou, China.
Li JJ; The First Department of Oncology.

Anticancer Drugs ; 34(3): 455-459, 2023 03 01.

Article in En | MEDLINE | ID: mdl-36730569

Subject(s)

Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Thrombocytopenia; Female; Humans; Middle Aged; Carcinoma, Non-Small-Cell Lung/drug therapy; Lung Neoplasms/drug therapy; ErbB Receptors/genetics; Protein Kinase Inhibitors/pharmacology; Mutation; Aniline Compounds/therapeutic use

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Thrombocytopenia / Carcinoma, Non-Small-Cell Lung / Lung Neoplasms Type of study: Diagnostic_studies Limits: Female / Humans / Middle aged Language: En Journal: Anticancer Drugs Journal subject: ANTINEOPLASICOS Year: 2023 Document type: Article Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google